Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a definitive agreement to sell 1,293,126 shares of common stock at $3.00 per share, raising approximately $7.76 million before expenses. The company will also issue warrants for 2,586,667 common shares and pre-funded warrants for 1,239,541 shares. Proceeds will be allocated to advancing its clinical pipeline and for general working capital. The deal is expected to close upon meeting all conditions, including stock exchange approval. Roth Capital Partners is the exclusive placement agent for this offering.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the enrollment of 15 patients in a Phase 2b viral challenge study for the intranasal therapy REVTx-99, targeting H3N2 influenza prevention. This study, conducted in Belgium, aims to evaluate REVTx-99's efficacy against respiratory viral infections by activating an innate immune response. The company expects topline data by Q2 2022.
REVTx-99 may also be applicable for SARS-CoV-2 and other respiratory viruses, addressing a significant need for new therapeutic options amid ongoing viral challenges.
Revelation Biosciences (NASDAQ: REVB) has initiated patient enrollment for a Phase 1b clinical study of REVTx-99, targeting allergic rhinitis and chronic nasal congestion. The randomized, placebo-controlled study aims to assess the safety and tolerability of REVTx-99, with results expected in the first half of 2022. Allergic rhinitis affects approximately 8% of adults and 7% of children in the U.S., increasing asthma risk. REVTx-99 is designed to stimulate the nasal immune system, offering a potential treatment for millions suffering from these conditions.
Revelation Biosciences Inc. (NASDAQ: REVB) reported a significant reduction of over 50% in SARS-CoV-2 Delta viral load after treatment with REVTx-99 in three independent in vitro assays. The company has completed its business combination with Petra Acquisition, Inc., effective January 11, 2022, and is listed under symbols REVB and REVBW. The investigational drug REVTx-99 stimulates protective immune responses and is being developed for multiple viral infections, including COVID-19 and influenza. The firm aims to advance its protective therapy amid the ongoing COVID-19 pandemic.